exclusion criteria of prime dose: * subjects with a medical or family history of convulsions, epilepsy, encephalopathy, and psychosis. * allergic to any ingredient in the study vaccine, or used to have a serious vaccine allergic reaction. * women who are positive for urine pregnancy test. women who are pregnant or breastfeeding or planning to be pregnant within 6 months. * have acute febrile diseases or infectious diseases. * history of sars, sars-cov-2 or mers infection. * people with serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, severe hypertension and can not control using drugs. * patients with severe chronic diseases or progressive conditions can not be smoothly controlled, such as asthma, diabetes, and thyroid diseases. * have congenital or acquired angioedema/neuroedema. * had urticaria 1 year before receiving the study vaccine. * asplenium or functional aspleen. * have thrombocytopenia or other coagulation disorders (may cause contraindications to intramuscular injection). * have acupuncture syncope reaction. * have received immunosuppressant therapy, anti-allergic therapy, cytotoxic therapy, inhaled corticosteroids in the past 6 months (excluding corticosteroid spray therapy for allergic rhinitis, and surface corticosteroid therapy for acute non-complicated dermatitis). * received blood products within 4 months before receiving the study vaccine. * received other study drugs within 1 month before receiving the study vaccine. * received a live attenuated vaccine within 1 month before receiving the study vaccine. * received a subunit or inactivated vaccine within 14 days before receiving the study vaccine. * are receiving anti-tuberculosis treatment. * according to the judgment of the researchers, due to a variety of medical, psychological, social or other conditions, it is contrary to the trial scheme, or affects the subjects to sign informed consent. * it is contrary to the trial protocol, or affects the subjects to sign informed consent due to various medical, psychological, social or other conditions, according to the investigator's judgment. exclusion criteria of subsequent dose: * have had a severe allergic reaction after the previous dose of vaccination. * those with serious adverse events that are causally related to the previous dose of vaccination. * for those newly discovered or occurred after the prime vaccination that does not meet the prime-dose inclusion criteria or meets the prime-dose exclusion criteria, it is up to the investigator to determine whether to continue to participate in the study or not. * other exclusion reasons determined by the investigators.

exclusion criteria of prime dose: * subjects with a medical or family history of convulsions, epilepsy, encephalopathy, and psychosis. * allergic to any ingredient in the study vaccine, or used to have a serious vaccine allergic reaction. * women who are positive for urine pregnancy test. women who are pregnant or breastfeeding or planning to be pregnant within 6 months. * have acute febrile diseases or infectious diseases. * history of sars, sars-cov-2 or mers infection. * people with serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, severe hypertension and can not control using drugs. * patients with severe chronic diseases or progressive conditions can not be smoothly controlled, such as asthma, diabetes, and thyroid diseases. * have congenital or acquired angioedema/neuroedema. * had urticaria 1 year before receiving the study vaccine. * asplenium or functional aspleen. * have thrombocytopenia or other coagulation disorders (may cause contraindications to intramuscular injection). * have acupuncture syncope reaction. * have received immunosuppressant therapy, anti-allergic therapy, cytotoxic therapy, inhaled corticosteroids in the past 6 months (excluding corticosteroid spray therapy for allergic rhinitis, and surface corticosteroid therapy for acute non-complicated dermatitis). * received blood products within 4 months before receiving the study vaccine. * received other study drugs within 1 month before receiving the study vaccine. * received a live attenuated vaccine within 1 month before receiving the study vaccine. * received a subunit or inactivated vaccine within 14 days before receiving the study vaccine. * are receiving anti-tuberculosis treatment. * according to the judgment of the researchers, due to a variety of medical, psychological, social or other conditions, it is contrary to the trial scheme, or affects the subjects to sign informed consent. * it is contrary to the trial protocol, or affects the subjects to sign informed consent due to various medical, psychological, social or other conditions, according to the investigator's judgment. exclusion criteria of subsequent dose: * have had a severe allergic reaction after the previous dose of vaccination. * those with serious adverse events that are causally related to the previous dose of vaccination. * for those newly discovered or occurred after the prime vaccination that does not meet the prime-dose inclusion criteria or meets the prime-dose exclusion criteria, it is up to the investigator to determine whether to continue to participate in the study or not. * other exclusion reasons determined by the investigators.

exclusion criteria of prime dose: - subjects with a medical or family history of convulsions, epilepsy, encephalopathy, and psychosis. - allergic to any ingredient in the study vaccine, or used to have a serious vaccine allergic reaction. - women who are positive for urine pregnancy test. women who are pregnant or breastfeeding or planning to be pregnant within 6 months. - have acute febrile diseases or infectious diseases. - history of sars, sars-cov-2 or mers infection. - people with serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, severe hypertension and can not control using drugs. - patients with severe chronic diseases or progressive conditions can not be smoothly controlled, such as asthma, diabetes, and thyroid diseases. - have congenital or acquired angioedema/neuroedema. - had urticaria 1 year before receiving the study vaccine. - asplenium or functional aspleen. - have thrombocytopenia or other coagulation disorders (may cause contraindications to intramuscular injection). - have acupuncture syncope reaction. - have received immunosuppressant therapy, anti-allergic therapy, cytotoxic therapy, inhaled corticosteroids in the past 6 months (excluding corticosteroid spray therapy for allergic rhinitis, and surface corticosteroid therapy for acute non-complicated dermatitis). - received blood products within 4 months before receiving the study vaccine. - received other study drugs within 1 month before receiving the study vaccine. - received a live attenuated vaccine within 1 month before receiving the study vaccine. - received a subunit or inactivated vaccine within 14 days before receiving the study vaccine. - are receiving anti-tuberculosis treatment. - according to the judgment of the researchers, due to a variety of medical, psychological, social or other conditions, it is contrary to the trial scheme, or affects the subjects to sign informed consent. - it is contrary to the trial protocol, or affects the subjects to sign informed consent due to various medical, psychological, social or other conditions, according to the investigator's judgment. exclusion criteria of subsequent dose: - have had a severe allergic reaction after the previous dose of vaccination. - those with serious adverse events that are causally related to the previous dose of vaccination. - for those newly discovered or occurred after the prime vaccination that does not meet the prime-dose inclusion criteria or meets the prime-dose exclusion criteria, it is up to the investigator to determine whether to continue to participate in the study or not. - other exclusion reasons determined by the investigators.

exclusion criteria of prime dose: - subjects with a medical or family history of convulsions, epilepsy, encephalopathy, and psychosis. - allergic to any ingredient in the study vaccine, or used to have a serious vaccine allergic reaction. - women who are positive for urine pregnancy test. women who are pregnant or breastfeeding or planning to be pregnant within 6 months. - have acute febrile diseases or infectious diseases. - history of sars, sars-cov-2 or mers infection. - people with serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, severe hypertension and can not control using drugs. - patients with severe chronic diseases or progressive conditions can not be smoothly controlled, such as asthma, diabetes, and thyroid diseases. - have congenital or acquired angioedema/neuroedema. - had urticaria 1 year before receiving the study vaccine. - asplenium or functional aspleen. - have thrombocytopenia or other coagulation disorders (may cause contraindications to intramuscular injection). - have acupuncture syncope reaction. - have received immunosuppressant therapy, anti-allergic therapy, cytotoxic therapy, inhaled corticosteroids in the past 6 months (excluding corticosteroid spray therapy for allergic rhinitis, and surface corticosteroid therapy for acute non-complicated dermatitis). - received blood products within 4 months before receiving the study vaccine. - received other study drugs within 1 month before receiving the study vaccine. - received a live attenuated vaccine within 1 month before receiving the study vaccine. - received a subunit or inactivated vaccine within 14 days before receiving the study vaccine. - are receiving anti-tuberculosis treatment. - according to the judgment of the researchers, due to a variety of medical, psychological, social or other conditions, it is contrary to the trial scheme, or affects the subjects to sign informed consent. - it is contrary to the trial protocol, or affects the subjects to sign informed consent due to various medical, psychological, social or other conditions, according to the investigator's judgment. exclusion criteria of subsequent dose: - have had a severe allergic reaction after the previous dose of vaccination. - those with serious adverse events that are causally related to the previous dose of vaccination. - for those newly discovered or occurred after the prime vaccination that does not meet the prime-dose inclusion criteria or meets the prime-dose exclusion criteria, it is up to the investigator to determine whether to continue to participate in the study or not. - other exclusion reasons determined by the investigators.